Passa al contenuto
Merck
  • Adverse effect of obesity on red cell membrane arachidonic and docosahexaenoic acids in gestational diabetes.

Adverse effect of obesity on red cell membrane arachidonic and docosahexaenoic acids in gestational diabetes.

Diabetologia (2003-11-25)
Y Min, K Ghebremeskel, C Lowy, B Thomas, M A Crawford
ABSTRACT

Gestational diabetes is a metabolic disorder affecting 2-5% of women and is a predictor of obesity, Type 2 diabetes mellitus and cardiovascular disease. Insulin resistance, a characteristic of gestational diabetes and obesity, is correlated with the fatty acids profile of the red cell and skeletal muscle membranes. We investigated the plasma and red cell fatty acid status of gestational diabetes. The effect of obesity on membrane fatty acids was also examined. Fasting blood obtained at diagnosis was analysed for the fatty acids in plasma choline phosphoglycerides and red cell choline and ethanolamine phosphoglycerides. There were reductions in arachidonic acid (controls 10.74+/-2.35 vs gestational diabetes 8.35+/-3.49, p<0.01) and docosahexaenoic acid (controls 6.31+/-2.67 vs gestational diabetes 3.25+/-2.00, p<0.0001) in the red cell choline phosphoglycerides in gestational diabetes. A similar pattern was found in the ethanolamine phosphoglycerides. Moreover, the arachidonic and docosahexaenoic acids depletion in the red cell choline phosphoglycerides was much greater in overweight/obese gestational diabetes (arachidonic acid=7.49+/-3.37, docosahexaenoic acid=2.98+/-2.18, p<0.01) compared with lean gestational diabetes (arachidonic acid=10.03+/-2.74, docosahexaenoic acid=4.18+/-1.42). Apparently normal plasma choline phosphoglycerides fatty acids profile in the gestational diabetic women suggested that membrane lipid abnormality is associated specifically with perturbation in the membrane. The fact that the lipid abnormality is more pronounced in the outer leaflet of the membrane where most of receptor binding and enzyme activities take place might provide an explanation for the increased insulin resistance in gestational diabetes and obesity.

MATERIALI
Numero di prodotto
Marchio
Descrizione del prodotto

Sigma-Aldrich
Acido oleico, technical grade, 90%
Sigma-Aldrich
Palmitic acid, ≥99%
Sigma-Aldrich
α-Linoleic acid, ≥98%
Sigma-Aldrich
Acido oleico, ≥99% (GC)
Sigma-Aldrich
Acido oleico, suitable for cell culture, BioReagent
Sigma-Aldrich
Acido linoleico, liquid, BioReagent, suitable for cell culture
Sigma-Aldrich
Palmitic acid, BioXtra, ≥99%
Sigma-Aldrich
Arachidonic acid, >95.0% (GC)
Sigma-Aldrich
Acido oleico, natural, FCC
Sigma-Aldrich
Acido oleico, meets analytical specification of Ph, Eur., 65.0-88.0% (GC)
Supelco
Palmitic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Arachidonic acid, from non-animal source, ≥98.5% (GC)
Sigma-Aldrich
Palmitic acid, ≥98%, FCC, FG
Sigma-Aldrich
Acido linoleico, technical, 58-74% (GC)
Supelco
Acido oleico, analytical standard
Supelco
Acido linoleico, analytical standard
Supelco
Palmitic acid, analytical standard
Sigma-Aldrich
Palmitic acid, ≥98% palmitic acid basis (GC)
Palmitic acid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Palmitic acid, natural, 98%, FG
Supelco
Palmitic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
Acido oleico, Selectophore, ≥99%